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ARTICLE
Significant Correction of Disease after Postnatal Administration
of Recombinant Ectodysplasin A in Canine X-Linked Ectodermal
Dysplasia
Margret L. Casal, John R. Lewis, Elizabeth A. Mauldin, Aubry Tardivel, Karine Ingold,
Manuel Favre, Fabrice Paradies,* Ste´phane Demotz, Olivier Gaide, and Pascal Schneider
Patients with defective ectodysplasin A (EDA) are affected by X-linked hypohidrotic ectodermal dysplasia (XLHED), a
condition characterized by sparse hair, inability to sweat, decreased lacrimation, frequent pulmonary infections, and
missing and malformed teeth. The canine model of XLHED was used to study the developmental impact of EDA on
secondary dentition, since dogs have an entirely brachyodont, diphyodont dentition similar to that in humans, as opposed
to mice, which have only permanent teeth (monophyodont dentition), some of which are very different (aradicular
hypsodont) than brachyodont human teeth. Also, clinical signs in humans and dogs with XLHED are virtually identical,
whereas several are missing in the murine equivalent. In our model, the genetically missing EDA was compensated for
by postnatal intravenous administration of soluble recombinant EDA. Untreated XLHED dogs have an incomplete set
of conically shaped teeth similar to those seen in human patients with XLHED. After treatment with EDA, significant
normalization of adult teeth was achieved in four of five XLHED dogs. Moreover, treatment restored normal lacrimation
and resistance to eye and airway infections and improved sweating ability. These results not only provide proof of concept
for a potential treatment of this orphan disease but also demonstrate an essential role of EDA in the development of
secondary dentition.
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In X-linked hypohidrotic ectodermal dysplasia (XLHED
[MIM #305100]) in humans (caused by a defect in ED1),
affected individuals have a developmental disorder char-
acterized by sparse or absent hair, missing and/or mal-
formed teeth, and hypoplastic eccrine glands.1–5 There is
significant morbidity and mortality in affected children
due to hyperthermia, caused by their inability to sweat.
Lack of other glands leads to an increased risk of respi-
ratory-tract infections and dry eye resulting in ocular dis-
ease.1,3,5,6 Tooth abnormalities include delayed primary
and secondary dentition, abnormal occlusion, conical
tooth crowns (peg-shaped teeth), and oligodontia, which
lead to difficulties with mastication, growth retardation,
poor appearance, and speech impairment.3,7,8
The proteins encoded by the two longest transcripts of
ED1 (EDA-A1 and EDA-A2) are type II transmembrane
proteins with a short intracellular domain, a transmem-
brane domain, a collagen motif, and a tumor necrosis fac-
tor (TNF)–ligand motif that associate into a homotrimer.9
An extracellular furin site allows for cleavage of the pro-
tein, making it a soluble ligand, which is required for bind-
ing to its receptor (EDAR) and for proper signaling. About
half the mutations causing XLHED are missense muta-
tions, most of which are located in either (1) the putative
transmembrane/extracellular junction domain, (2) the fu-
rin cleavage site, (3) the collagenous domain, which is
thought to be necessary for ligand oligomerization, or
(4) the TNF domain, which mediates receptor binding.10
These mutations either alter the overall structure and fold-
ing of ectodysplasin A (EDA) or specifically impair one of
the functional domains.
In recent experiments, recombinant EDA (Fc:EDA1) was
administered pre- and postnatally to Tabby mice, the mu-
rine homologue of humans and canines with XLHED.11
The protein was designed such that, when injected intra-
venously (IV) into pregnant dams, the Fc portion (of hu-
man immunoglobulin G1) would allow for transfer across
the placenta into the affected fetus.11 Because there is vir-
tually no intrauterine transfer of immunoglobulins in
dogs, we chose to treat the XLHED dogs postnatally. This
also more closely reflects the clinical situation, in which
the diagnosis is often not made until after birth unless
there is a family history of ectodermal dysplasia. Postnatal
injections in neonatal Tabby mice resulted in normaliza-
tion of the eyelid opening and the appearance of sweat
glands and tail hair. However, correction of the lack of ear
hair, guard and zigzag hair, and abnormal molar shape
was achieved only when fetal Tabby mice, but not neo-
natal mice, were exposed to the recombinant protein.
We chose to use the canine model12 for further thera-
peutic trials with Fc:EDA1, because the disease in dogs
more closely mirrors that seen in human patients. In our
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Table 1. Injection Protocol
Age
(d)
Fc:EDA1 Injection per Protocol
(mg)
T1x1a T4x1b T5x2c
2 1 1 2
5 … 1 2
8 … 1 2
11 … 1 2
14 … … 2
NOTE.—XLHED dogs received Fc:EDA1 IV at
doses and ages specified in the table.
a The T1x1 protocol used three dogs: one
male and two female.
b The T4x1 protocol used one female dog.
c The T5x2 protocol used five male dogs.
model, XLHED is caused by a point mutation in the splice-
acceptor site of intron 8, which results in a truncated,
nonfunctional protein.13 The XLHED dogs have symmet-
rical hairlessness, nasal crusting, and dry eye from de-
creased lacrimation and are unable to sweat. As in most
human patients with XLHED, we have found an increased
rate of pulmonary infectious diseases, attributable to the
lack of bronchial glands, which are necessary for normal
ciliary function.14
The tooth abnormalities are also quite similar, in that
the number of teeth is greatly reduced, and those teeth
that are present are generally all peg shaped in affected
dogs. Tooth development in dogs and humans is very sim-
ilar: deciduous teeth are formed before birth, erupt after
birth, and are followed by permanent teeth, which de-
velop as a bud arising from the dental lamina of the de-
ciduous tooth.15 Adult humans and dogs have brachyo-
dont dentition consisting of 32 and 42 teeth, respectively,
including incisors, canines, premolars, and molars. Mice
differ in that they have only 16 permanent teeth, with
incisors that grow continuously (aradicular hypsodont),
and they lack canines and premolars.16,17 In the Tabby
mouse, the third molar is missing in ∼50% of the mice,
the teeth are generally smaller, and molars have less prom-
inent cusps,18,19 but the overall appearance is not dramat-
ically different from that of normal mice. In this study,
we demonstrate that postnatal administration of Fc:EDA1
in dogs has a prominent effect on permanent dentition
and significantly improves long-term resistance to eye and
airway infections, probably through restoration of glan-
dular functions.
Material and Methods
Treatment and Analysis of XLHED Dogs
All dogs were cared for in accordance with the principles outlined
in the National Institutes of Health Guide for the Care and Use
of Laboratory Animals and in the International Guiding Princi-
ples for Biomedical Research Involving Animals. Affected females
were produced by breeding heterozygous females to XLHED
males, and their phenotype does not differ from that seen in male
dogs. Three affected pups (two females and one male) received a
single injection of 1 mg (3–4 mg/kg) of Fc:EDA111 IV via the
jugular vein at age 2 d (T1x1 protocol) (table 1). One female
XLHED pup was injected with 1 mg Fc:EDA1 at ages 2, 5, 8, and
11 d (T4x1 protocol), and five male XLHED dogs received a higher
dose of 2 mg (6–7 mg/kg) of Fc:EDA1 at ages 2, 5, 8, 11, and 14
d (T5x2 protocol). The clinical appearances of hair, teeth, eyes,
and sweat glands were evaluated in the treated and sex-matched
control (nontreated) XLHED dogs, as were other clinical signs of
disease. Dental examinations were performed at ages 4 wk (when
eruption of deciduous teeth begins), 8–12 wk (when all deciduous
teeth are present), 16 wk (when eruption of adult teeth begins),
and 36 wk (when all adult teeth are present), with attention paid
to the presence or absence of teeth, crown shape, and tooth lo-
cation. Intraoral radiographs were obtained from all dogs in the
study with the use of dental film (D-speed, size 4 [Kodak]) and a
dental radiograph machine (Schick CDR Discovery DC 60/70).
Radiographs of the maxilla and rostral mandible were taken using
the bisecting-angle technique, whereas radiographs of the caudal
mandible were taken using the parallel technique.20
Lacrimal Function
The Shirmer tear testing was performed 30 min after oral treat-
ment with 4 mg pilocarpine HCl 1% (a cholinergic agent with
muscarinic action that increases secretion from exocrine glands
[Alcon Laboratories]), to standardize tear production. Shirmer tear
test strips (Schering Plough) were placed into the medial canthus
of each eye, and the amount of fluid produced was determined
by measuring the length of the resulting blue dye after 1 min.
XLHED dogs produce ∼25% less lacrimal fluid than do wild-type
dogs.
Sweat Testing
As opposed to humans, dogs and mice have eccrine sweat glands
only in their footpads. To assess sweat-gland function in the dog,
we developed a modified starch-iodine sweating assay. Wild-type
and XLHED-affected dogs were given 4 mg pilocarpine orally.
Thirty minutes later, the footpads of one paw were painted with
3% (wt/vol) iodine in ethanol. After 1 min, the paw was placed
on a Whatman No. 3 filter paper coated with cornstarch. The
paw was held in place for 1 min, to allow the iodine in the pres-
ence of sweat droplets to mix with the cornstarch, resulting in
dark brown spots on the filter paper. The procedure was then
repeated for the other paws. Semiquantitative measurements
were obtained by scanning the filter papers, calculating the area
of the footpad, and calculating the area of brown staining caused
by sweating, with the use of Image-Pro (Media Cybernetics), a
computer imaging analysis software. The ratio of the brown stain-
ing was divided by the area of the footpad and was multiplied
by 100 to give the percentage of sweat-droplet coverage of the
footpad. Testing was performed at least three times at 1-mo in-
tervals for each dog after age 16 wk, at which time sweat glands
are fully functional in wild-type dogs.
Mucociliary Clearance
To examine the effect of absent bronchial glands, mucociliary
clearance studies were performed in 6-mo-old dogs. One radio-
active marker was taped to the lateral chest wall at the level of
the carina (fifth intercostal space), and a second marker was taped
15–20 cm cranial at the level of the trachea, depending on the
size of the dog. With the use of general anesthesia and a sleeved
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Table 2. Outcome of Treatment of XLHED-Affected Dogs with Fc:EDA1
Clinical Observation
Untreated
( )np 30
T1x1a
( )np 3
T4x1b
( )np 1
T5x2c
( )np 5
Improved weight gain 0 3 1 5
Normal lacrimation 0 3 1 5
Ability to sweat 0 2 1 4
Full set of adult teethd 0 0 0 4
Normalization of shape of some teeth 0 0 0 4
Mucociliary clearance 0 2 1 4
Bronchopneumonia 16 0 1 0
Change in hair distribution 0 0 0 0
a One milligram given IV at age 2 d.
b One milligram given IV at ages 2, 5, 8, and 11 d.
c Two milligrams given IV at ages 2, 5, 8, 11, and 14 d.
d Dogs in which there was no significant difference in number of teeth when com-
pared with normal dogs.
Table 3. Effect of Treatment with Fc:EDA1 on Dentition
Group n
No. of Teeth
(MeanSD)
Incisor Canine Premolar Molar
Wild type 5 12.0.0 4.0.0 15.21.2 10.0.0
Untreated XLHED 5 6.82.6a 3.21.1 4.2.8a 9.6.5
Treated XLHED 5 10.03.5b 3.8.4 10.65.4b 9.01.0
Treated XLHEDc 4 11.8.5b 3.8.5 12.82.8b 9.51.0
a Significant difference at between untreated XLHED-affectedP ! .05
dogs and normal dogs.
b Significant difference at between untreated XLHED-affectedP ! .05
dogs and XLHED-affected dogs treated with the T5x2 protocol.
c Results from treated group, with the data from the dog that did not
respond to treatment removed.
polystyrene catheter, a droplet (25–50 ml) of 99mTechnetium-
macroaggregated albumin containing 200–300 mCi of radioactiv-
ity was placed through the intubation tube onto the tracheal
mucosa at the level of the distal (carina) marker. Static images
were acquired with the Technicare Omega 500 camera interfaced
with a NuQuest Veterinary nuclear medicine computer every 5
min for 20–30 min, and the tracheal mucociliary velocity (in mm/
min) was calculated using these images.21 The dogs were clin-
ically healthy, and there was no indication of respiratory disease
at the time of the study.
Statistical Analysis
Statistical analyses were performed using the Mann-Whitney
test (nonparametric) for small sample sizes that were not distrib-
uted normally (InStat version 2.03 for Macintosh [GraphPad
Software]).
Results
Normally, untreated XLHED dogs show a decrease in
weight gain at age ∼2 d when compared with their normal
and heterozygote littermates. With proper supplementa-
tion and care, the XLHED pups usually become equal in
size and weight to their littermates by ages 2–3 wk. In this
study, all dogs that received Fc:EDA1 gained weight with-
out supplementation at a rate comparable to their wild-
type littermates, but no change in hair growth develop-
ment was observed (table 2). None of the treated dogs
showed any side effects during or after the injections.
Whereas wild-type adult dogs have a total of 12 incisor,
4 canine, 16 premolar, and 10 molar teeth, with the oc-
casional absence of 1 or 2 premolars or molars, XLHED
dogs have a significant reduction in incisors ( )Pp .008
and premolars ( ) (table 3). Although no overt res-Pp .008
cue of deciduous tooth abnormalities was observed, four
of five XLHED dogs that received the extended T5x2
protocol developed an almost full set of adult teeth, with
no significant differences from wild type when incisors
( ) and premolars ( ) were compared (tablePp .31 Pp .10
3). Many of the incisor teeth and some of the canines,
premolars, and molars of the dogs that responded to treat-
ment were clinically and radiographically normal (fig. 1).
The most common abnormality noted in the dentition of
the XLHED dogs in the T5x2 group was slightly narrowed
canine teeth compared with those of normal age- and size-
matched control dogs (fig. 1A and 1B). In affected dogs,
the maxillary canine teeth were tipped forward (mesiov-
ersion), and the mandibular canines often exhibited both
mesioversion and labioversion (outward tipping) (fig. 1C).
The positioning of the canines was markedly improved in
the T5x2-protocol treated XLHED dogs, so that no cor-
rective orthodontic procedures were necessary. At age 2
years, the dentition remains corrected, with no changes
in tooth position or loss of structure in the oldest of the
T5x2-protocol dogs.
Mucociliary clearance studies were performed to eval-
uate the effect of Fc:EDA1 on respiratory clearance func-
tions in treated and untreated dogs. As expected, muco-
ciliary clearance was decreased in affected untreated dogs
when compared with wild-type dogs (fig. 2). Two of the
dogs that received single injections of Fc:EDA1 at age 2 d
were able to clear a radioactive tracer at approximately
the same rate as the heterozygote dogs, whereas the third
dog in this group showed a lower clearance rate (5.50.5
cm/min), which was not significantly different from that
found in affected dogs (4.53.5 cm/min). Dogs that re-
ceived multiple injections showed the highest clearance
rate of all the treated dogs, exceeding even heterozygote
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Figure 1. Photographs (A and C) and mandibular dental radiographs (B and D) of wild-type (right), untreated XLHED (left), and treated
XLHED (middle) dogs. All incisor and canine teeth were present in the XLHED dog treated with Fc:EDA1 (A and B). The maxillary incisors
are normal in shape and number, but both mandibular first incisors and canine teeth were narrowed in diameter compared with their
normal counterparts (A). The number of adult premolars is increased in the XLHED dog treated with Fc:EDA1 in comparison with the
untreated control XLHED dog, in which most premolars were absent (C). The third premolar (arrow) has the radiographic appearance of
a deciduous tooth (D). However, it appears to be an adult tooth on the basis of the clinical appearance of its crown.
Figure 2. Mucociliary clearance in XLHED dogs after a single-
dose (T1x1, ) or multiple-dose (T4x1, ; T5x2, ;np 3 np 1 np 5
and T5x2*, ) treatment with Fc:EDA1. Multiple measurementsnp 4
were obtained for each dog on separate days, to obtain a mean
and SD. For illustrative purposes, the data from the dog that did
not respond to treatment were removed from the group (T5x2*)
and are shown separately (T5x2**).
levels (fig. 2). However, in one of the XLHED dogs that
underwent the T5x2 protocol and also did not sweat, nei-
ther clearance (5.450 cm/min) nor dentition improved
(table 2).
Although bronchopneumonia occurred at a rate of
150% in untreated XLHED dogs,14 sometimes in a recur-
rent manner, none of the treated XLHED dogs showed
any clinical signs of disease, with the exception of the
T4x1 protocol dog (table 2). This dog had a body tem-
perature of 40.5C (normal 38.3C–38.9C) and increased
respiratory sounds over the left medial lung field, consis-
tent with a mild pneumonia, which were resolved after a
short course of antibiotics.
XLHED dogs produce ∼25% less lacrimal fluid than do
wild-type dogs, which may contribute to frequent neo-
natal eye infections (in 190% of XLHED dogs) and kera-
toconjunctivitis sicca in older affected dogs.14 For dogs
given single injections and dogs given multiple injections
of either 1 or 2 mg Fc:EDA1, tear production was greatly
improved and often approached or exceeded wild-type
levels (fig. 3). Neonatal eye infections or keratoconjunc-
tivitis sicca were not observed in any of the treated dogs
at any age (table 2).
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Figure 3. Lacrimal secretions in XLHED dogs after a single-dose
(T1x1) or multiple-dose (T4x1 and T5x2) treatment with Fc:EDA1,
in percentage of wild type (SD). The SD is too small to be seen
in the normal dogs.
Figure 4. Semiquantitative sweat testing in XLHED dogs after a
single-dose (T1x1, ) or multiple-dose (T4x1, ; T5x2,np 3 np 1
; and T5x2*, ) treatment with Fc:EDA1. The ability tonp 5 np 4
sweat was measured on all four feet after oral administration of
pilocarpine to induce sweating. For illustrative purposes, the data
from the dog that did not respond to treatment were removed from
the group (T5x2*).
We have found that, in wild-type dogs, eccrine sweat
glands are present microscopically at birth but are not
fully developed and do not respond to pilocarpine, a cho-
linergic agent, until age 16 wk. Hence, we assessed the
ability to sweat at later time points, using the modified
starch-iodine sweat test,11 in wild-type dogs, heterozygote
dogs, untreated XLHED dogs, and Fc:EDA1-treated XLHED
dogs. By age 28 wk, a few sweat droplets were observed
in the foot pads of two of the three XLHED dogs of the
T1x1 protocol, and multiple sweat droplets were observed
in all footpads (one large palmar and four smaller toe foot-
pads) of the T4x1 protocol dog. Sweat testing at age 13
mo revealed sweat droplets that were often too numerous
to count in four of the five T5x2 dogs (fig. 4 and table 2).
Discussion
The current experiment showed that postnatal adminis-
tration of a recombinant protein in dogs with XLHED, a
developmental genetic disease, was able to induce a more
complete and anatomically correct adult dentition and to
partially or totally rescue a number of other morphological
and pathological features of the disease. In mice, tooth
correction by postnatal administration of Fc:EDA1 was
never observed.11 However, with use of the highest-dosing
protocol, four of five XLHED dogs developed a nearly full
set of permanent teeth with near-normal appearance of
the crowns. The murine and canine data suggest that the
treatment must be administered before the development
of the permanent teeth, which occurs earlier in mice be-
cause they lack a deciduous dentition. In the one dog that
did not appear to respond to the T5x2 treatment (here-
after, called the “poorly responsive” dog), only 4 of 12
incisors, 4 of 4 canines, 2 of 16 premolar teeth, and 8 of
10 molar teeth were present. Mucociliary clearance and
sweating ability did not improve in this dog either, but
lacrimation was normalized. Failure of Fc:EDA1 to rescue
dentition in this dog was not due to the development of
neutralizing antibodies (data not shown), which raises
the question of whether the threshold for Fc:EDA1 action
varies between individual, noninbred dogs. Of note, the
T1x1 ( ) and T4x1 ( ) protocols did not improvenp 3 np 1
tooth phenotype, despite improvement of other clinical
parameters, such as lacrimation. This suggests that a pos-
itive response of the secondary dentition to treatment re-
quires either higher concentrations of Fc:EDA1 or the pres-
ence of Fc:EDA1 at later time points ∼14 d after birth.
Basic development of deciduous and adult dentition in
the dog follows the same pattern as that described in hu-
mans. Formation of the dental lamina has been shown to
begin at 25 d of the 63-d gestation in the dog and, in
humans, between the 5th and 6th wk of gestation. The
dental lamina gives rise to tooth buds of the deciduous
teeth. The first tooth buds for permanent teeth form in
humans around the 17th wk of gestation until age 5 years.
Studies performed in canine fetuses demonstrate the pres-
ence of tooth buds for some permanent premolars and
molars at 42 d gestation and the emergence of tooth buds
for the first premolars (a permanent tooth in the dog with-
out deciduous predecessor). However, little is known re-
garding timing of the formation of the other tooth buds.22
In the XLHED dog, molars are present yet misshapen.
Treatment with the recombinant protein does not appear
to affect these teeth, yet all the teeth that are preceded by
deciduous teeth show responses to treatment with Fc:
EDA1. Perhaps incompletely developed deciduous teeth
of affected dogs are capable of inducing postnatal devel-
opment of permanent tooth buds after administration of
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the protein that would have otherwise not developed in
affected dogs. Experiments are currently under way, ex-
amining tooth development to understand why recom-
binant protein so profoundly affects tooth development
in affected dogs.
After treatment with Fc:EDA1, no change in hair growth
development was observed. In the normal dog, the first
tactile hair follicles are recognized at 30–32 d gestation
(canine pregnancy is 63 d), and they develop into whiskers
by 38 d.23 By 43 d gestation, hair follicles are present, and,
at 45 d, the body hair begins to form. The hair cover is
complete by 53 d, ∼10 d before birth. Histological studies
that use conventional12 and electron microscopy (M. L.
Casal and E. A. Mauldin, unpublished data) have shown
that affected dogs have a complete absence of hair follicles
in affected areas at birth. Therefore, it is likely that the
treatment was administered too late during development
to change hair growth. Interestingly, postnatal treatment
of Tabby mice with the recombinant protein resulted in
restoration of some hair.11 However, normal mice are born
hairless, unlike dogs, suggesting that the specific triggering
events have already taken place at birth, resulting in an
unresponsiveness of the canine ectodermal structures to
the effects of the protein. These results suggest that post-
natal treatment may be effective in human patients with
XLHED, since there are two waves of scalp hair growth in
the neonatal child, which is complete by ages 8–12 wk.24,25
In human patients, lacrimation is reduced, and Mei-
bomian glands may be hypoplastic or missing. Dry eye is
a significant problem requiring daily lubrication and leads
to corneal lesions and scarring if left untreated.3 In our
XLHED dogs, lacrimation is reduced by ∼25%, but Mei-
bomian glands are present and appear to function nor-
mally. The 25% reduction must therefore be significant
enough to cause dry eye similar to that found in human
patients. The results presented here demonstrate long-
term stable correction of lacrimation with even the lowest
dose of the recombinant protein, suggesting that devel-
opment of the lacrimal glands is not complete at the time
of treatment. Neonatal administration of the recombinant
protein led to a significant improvement of the quality of
life, by preventing the need to apply eye medications twice
daily to avoid corneal lesions.
The higher doses and longer administration of Fc:EDA1
appeared to increase the degree of sweating in the affected
dogs. Sweat testing was performed on a monthly basis,
and the results for each dog remained virtually the same
once they were old enough to sweat, demonstrating the
durability of the treatment. Whereas all protocols used
resulted in complete correction of lacrimation, the lower
dose appears to be insufficient to induce sweating to any
degree that would be therapeutic. It is not clear why sweat-
ing was not induced in the poorly responsive dog of the
T5x2 protocol, despite normalization of lacrimal function.
A higher dose of EDA might have been required in this
particular dog if some variation exists in disease expression
of XLHED. To our knowledge, the onset of eccrine gland
development in the dog is not known, but we have shown
that normal dogs are born with incompletely functional
but formed glands, suggesting that, for a more complete
reversion, treatment would have to be initiated earlier in
life. The inability of humans with XLHED to sweat causes
most of the morbidity and mortality associated with this
disease. These results and those from the Tabby mouse
studies suggest that the recombinant protein can perma-
nently induce and maintain the ability to sweat.
The lack of eccrine (serous) glands in the respiratory
tract of individuals with XLHED prevents the cilia from
moving freely, resulting in reduced pulmonary clearance
of pathogens. Therefore, respiratory-tract infections are
common in humans with XLHED3 and in affected dogs.14
Heterozygote dogs exhibit about 2/3 of wild-type muco-
ciliary clearance, which appears sufficient for function,
since the heterozygotes had no clinical signs compatible
with pulmonary disease. At all dosing protocols, there was
improvement in mucociliary clearance in all but two dogs,
one of which received the lowest dose. Clearance also did
not improve in the poorly responsive XLHED dog of the
T5x2 protocol, in which a higher dose might have been
required to correct dentition, sweating, and mucociliary
clearance.
In summary, the therapeutic action of Fc:EDA1 was not
restricted to its effect on adult teeth but also improved
weight gain (nine of nine dogs), restored wild-type levels
of lacrimation, preventing eye infections and keratocon-
juctivitis sicca (nine of nine dogs), induced the formation
of moderate numbers of functional sweat glands (seven
of nine dogs), and significantly improved mucociliary
clearance in the respiratory tract (seven of nine dogs) that
correlated with the marked decrease of pulmonary dis-
eases in the treated dogs (eight of nine dogs; at least 50%
of untreated XLHED dogs develop bronchopneumonia).
However, patterned hypotrichosis was not corrected (zero
of nine dogs), most likely because hair-differentiation
fate in the dog is a prenatal event. These findings have
implications for the treatment of human patients with
XLHED, because the diagnosis is often not made until after
birth, and postnatal treatment may still result in improve-
ment of clinical features of the disease.
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Web Resource
The URL for data presented herein is as follows:
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for XLHED)
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